Canestaro WJ - Search Results

1

Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.

Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, Shrank WH, Choudhry NK. Canestaro WJ, et al. Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):724-31. doi: 10.1161/CIRCOUTCOMES.113.000661. Epub 2013 Nov 12. Circ Cardiovasc Qual Outcomes. 2013. PMID: 24221832

2

Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.

Desai NR, Canestaro WJ, Kyrychenko P, Chaplin D, Martell LA, Brennan T, Matlin OS, Choudhry NK. Desai NR, et al. Among authors: canestaro wj. Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):694-9. doi: 10.1161/CIRCOUTCOMES.113.000321. Epub 2013 Nov 5. Circ Cardiovasc Qual Outcomes. 2013. PMID: 24192573

3

Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels.

Wang B, Canestaro WJ, Choudhry NK. Wang B, et al. Among authors: canestaro wj. JAMA Intern Med. 2014 Dec;174(12):1938-44. doi: 10.1001/jamainternmed.2014.5266. JAMA Intern Med. 2014. PMID: 25317785

4

Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing.

Canestaro WJ, Brooks DG, Chaplin D, Choudhry NK, Lawler E, Martell L, Brennan T, Wassman ER. Canestaro WJ, et al. J Pers Med. 2012 Oct 17;2(4):158-74. doi: 10.3390/jpm2040158. J Pers Med. 2012. PMID: 25562358 Free PMC article.

5

The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.

Carlson JJ, Canestaro W, Ravelo A, Wong W. Carlson JJ, et al. J Med Econ. 2017 Jul;20(7):671-677. doi: 10.1080/13696998.2017.1302453. Epub 2017 Mar 23. J Med Econ. 2017. PMID: 28332433 Free article. Clinical Trial.

6

Healthcare payers: a gate or translational bridge to personalized medicine?

Canestaro WJ, Martell LA, Wassman ER, Schatzberg R. Canestaro WJ, et al. Per Med. 2012 Jan;9(1):73-84. doi: 10.2217/pme.11.77. Per Med. 2012. PMID: 29783295

7

Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use.

Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Chin L, et al. AMIA Jt Summits Transl Sci Proc. 2017 Jul 26;2017:30-39. eCollection 2017. AMIA Jt Summits Transl Sci Proc. 2017. PMID: 28815101 Free PMC article.

8

Favorable and publicly funded studies are more likely to be published: a systematic review and meta-analysis.

Canestaro WJ, Hendrix N, Bansal A, Sullivan SD, Devine EB, Carlson JJ. Canestaro WJ, et al. J Clin Epidemiol. 2017 Dec;92:58-68. doi: 10.1016/j.jclinepi.2017.08.004. Epub 2017 Aug 31. J Clin Epidemiol. 2017. PMID: 28842289 Review.

9

Implications of employer coverage of contraception: Cost-effectiveness analysis of contraception coverage under an employer mandate.

Canestaro W, Vodicka E, Downing D, Trussell J. Canestaro W, et al. Contraception. 2017 Jan;95(1):77-89. doi: 10.1016/j.contraception.2016.08.002. Epub 2016 Aug 16. Contraception. 2017. PMID: 27542519 Free PMC article.

10

Capsule Commentary on Phibbs et. al., At-Home versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS).

Canestaro WJ. Canestaro WJ. J Gen Intern Med. 2016 Sep;31(9):1082. doi: 10.1007/s11606-016-3751-x. J Gen Intern Med. 2016. PMID: 27216482 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters